NESS ZIONA, Israel, Feb. 03, 2026 (GLOBE NEWSWIRE) — Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present new safety and efficacy data from the GA Depot Phase II study in primary progressive multiple sclerosis (PPMS) at the ACTRIMS Forum 2026 Conference, to take place February 5-7, 2026, in San Diego, CA.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
